Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599324 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT02599324: Completed Phase 1 study, sponsored by Pharmacyclics.
NCT02599324 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 263 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02599324, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Primary Outcome
A DLT was defined as any Grade 3 (severe) or higher non-hematologic or Grade 4 (life-threatening) hematologic adverse event (AE) occurring during the DLT observation period that was considered to be at least possibly related to the study treatment (ibrutinib or drug combination).
Interventions
- DRUG cetuximab
- DRUG docetaxel
- DRUG paclitaxel
- DRUG ibrutinib
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2021-08-20 |
| Phase | Phase 1 |
What the finished NCT02599324 record still lists
NCT02599324 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher).
The record links to 0 conditions, and to 5 interventions - of which cetuximab is the first listed.
NCT02599324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02599324 about?
NCT02599324 is a clinical study titled "Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors". The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
What is the current status of trial NCT02599324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2015-12-01. Estimated completion is 2021-08-20.
What interventions are being tested in trial NCT02599324?
The interventions under investigation include: cetuximab (DRUG), docetaxel (DRUG), paclitaxel (DRUG), ibrutinib (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT02599324?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02599324's enrollment target sits among peer trials
263 158th of 2000 higher than 1,842 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI